Ergoteles LLC Sells 16,155 Shares of Magenta Therapeutics, Inc. (NASDAQ:MGTA)

Ergoteles LLC cut its holdings in Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) by 12.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 115,122 shares of the company’s stock after selling 16,155 shares during the period. Ergoteles LLC’s holdings in Magenta Therapeutics were worth $162,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in MGTA. Wellington Management Group LLP purchased a new position in shares of Magenta Therapeutics during the 1st quarter worth about $3,786,000. Laurion Capital Management LP purchased a new position in shares of Magenta Therapeutics during the 2nd quarter worth about $699,000. Woodline Partners LP boosted its stake in shares of Magenta Therapeutics by 201.1% during the 1st quarter. Woodline Partners LP now owns 796,461 shares of the company’s stock worth $2,310,000 after purchasing an additional 531,984 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Magenta Therapeutics by 205.7% during the 2nd quarter. Renaissance Technologies LLC now owns 731,346 shares of the company’s stock worth $878,000 after purchasing an additional 492,081 shares during the period. Finally, Millennium Management LLC boosted its stake in shares of Magenta Therapeutics by 33.6% during the 2nd quarter. Millennium Management LLC now owns 1,875,395 shares of the company’s stock worth $2,250,000 after purchasing an additional 471,594 shares during the period. 76.68% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, major shareholder Rock Ventures Iv L.P. Third sold 2,200,000 shares of Magenta Therapeutics stock in a transaction on Tuesday, February 7th. The stock was sold at an average price of $0.83, for a total value of $1,826,000.00. Following the transaction, the insider now directly owns 4,558,204 shares in the company, valued at approximately $3,783,309.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 11.56% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. HC Wainwright started coverage on shares of Magenta Therapeutics in a research note on Tuesday, February 28th. They set a “neutral” rating for the company. BTIG Research lowered Magenta Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, January 26th. Cowen restated a “market perform” rating on shares of Magenta Therapeutics in a report on Thursday, January 26th. Finally, Wedbush downgraded Magenta Therapeutics from an “outperform” rating to a “neutral” rating in a report on Thursday, January 26th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $4.33.

Magenta Therapeutics Stock Up 2.8 %

MGTA opened at $0.81 on Wednesday. The stock’s fifty day moving average is $0.64 and its two-hundred day moving average is $1.08. The company has a market capitalization of $49.16 million, a P/E ratio of -0.63 and a beta of 2.10. Magenta Therapeutics, Inc. has a 52 week low of $0.32 and a 52 week high of $3.62.

About Magenta Therapeutics

(Get Rating)

Magenta Therapeutics, Inc is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers patient preparation, stem cell collection, cell dose, and safe immune regeneration programs. Its platform include autologous and allogeneic transplant, and gene therapy.